studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 835A
where the average MELD score at transplantation is higher than
previously published studies. Methods: This is a single center
retrospective study designed to asses risk factors associated
with ACR status post adult orthotopic liver transplant (OLT).
Recipient demographics, preoperative clinical and laboratory
data and cytomegalovirus (CMV) immune status were recorded
for each transplant. Diagnosis of ACR was confirmed by biopsy
using the Banff schema for grading liver allograft rejection. Univariate
and multivariate regressions were preformed to look for
variables that are significant predictors of ACR. Results: This
study included 178 consecutive OLT patients transplanted in
our center from January 2008 to June 2013 at the University
of Illinois Hospital. Only 49.4% (88/178) of patients were
Caucasians. In this study population, the average MELD at
transplantation was 27.6, which is much higher than previously
published studies that looked into risk factors of ACR.
The average time from transplant to ACR diagnosis was 283.9
days. Majority of ACR episodes were mild/moderate and only
8.5% were graded as severe based on Banff classification.
Of the twenty-two characteristics analyzed, creatinine was a
significant predicator for ACR in both univariate and multivariate
models. Patients with creatinine elevation greater than 2.7
mg/dL have lower rates of ACR. Underlying liver etiology was
also studied and patients with either primary biliary cirrhosis
(PBC) or primary sclerosing cholangitis (PSC) have significantly
higher rates of ACR. Conclusion: The study confirmed a change
regarding the timing and severity of ACR in MELD era. Recipient
characteristics such as elevated creatinine and PBC/PSC
background may affect the risk of ACR and should be taken
into consideration when managing immunosuppression.
Disclosures:
The following authors have nothing to disclose: Mengyuan Liu, Kelly Galen,
Grace Guzman, Hoonbae Jeon, Costica Aloman
1267
Pre-Transplant Sarcopenia Does Not Reverse After Successful
Liver Transplantation
Trushar Patel, Valery Vilchez, Roberto Gedaly, Rashmi T. Nair,
Anna Christina Dela Cruz, Terrence Barrett; University of Kentucky,
Lexington, KY
Objective: To study the evolution of pre-transplant Sarcopenia
after successful Liver Transplantation and compare survival of
sarcopenic and non-sarcopenic patients Methods: Patients who
underwent liver transplantation between 2008 and 2013 at
our center were analyzed. We used CT scan at third lumbar
vertebrae to analyze with the SliceOmetic 5.0 software (Tomovision,
Canada) which enables specific tissue demarcation using
previously reported Hounsfield unit (HU) thresholds. Cutoffs for
sarcopenia were based on a CT-based sarcopenia study for
patients with malignancies (Skeletal Muscle Index (SMI)